The US FDA and the European Medicines Agency (EMA) have approved the use of two PARP inhibitor monotherapies, olaparib and talazoparib, in patients with suspected or confirmed deleterious gBRCA mutations and HER2-negative BC. This evidence concerns the gene ERBB2 and breast cancer.